457 related articles for article (PubMed ID: 27322698)
1. Comparison of Demographics, Tumor Characteristics, and Survival Between Pancreatic Adenocarcinomas and Pancreatic Neuroendocrine Tumors: A Population-based Study.
Yadav S; Sharma P; Zakalik D
Am J Clin Oncol; 2018 May; 41(5):485-491. PubMed ID: 27322698
[TBL] [Abstract][Full Text] [Related]
2. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.
Kuo EJ; Salem RR
Ann Surg Oncol; 2013 Sep; 20(9):2815-21. PubMed ID: 23771245
[TBL] [Abstract][Full Text] [Related]
3. Early onset pancreatic malignancies: Clinical characteristics and survival associations.
Beeghly-Fadiel A; Luu HN; Du L; Shi C; McGavic DP; Parikh AA; Raskin L
Int J Cancer; 2016 Nov; 139(10):2169-77. PubMed ID: 27416564
[TBL] [Abstract][Full Text] [Related]
4. Life expectancy in pancreatic neuroendocrine cancer.
Brooks JC; Shavelle RM; Vavra-Musser KN
Clin Res Hepatol Gastroenterol; 2019 Feb; 43(1):88-97. PubMed ID: 30220478
[TBL] [Abstract][Full Text] [Related]
5. Grade 3 Pancreatic Neuroendocrine Tumors on MDCT: Establishing a Diagnostic Model and Comparing Survival Against Pancreatic Ductal Adenocarcinoma.
Chen HY; Zhang XY; Deng XY; Ge YL; Tang YQ; Cui H; Yang B; Pan Y; Shi D; Yu RS
AJR Am J Roentgenol; 2020 Aug; 215(2):390-397. PubMed ID: 32432906
[No Abstract] [Full Text] [Related]
6. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival.
Halfdanarson TR; Rabe KG; Rubin J; Petersen GM
Ann Oncol; 2008 Oct; 19(10):1727-33. PubMed ID: 18515795
[TBL] [Abstract][Full Text] [Related]
7. Differences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States: A Multicenter Study.
Zhu LM; Tang L; Qiao XW; Wolin E; Nissen NN; Dhall D; Chen J; Shen L; Chi Y; Yuan YZ; Ben QW; Lv B; Zhou YR; Bai CM; Chen J; Song YL; Song TT; Lu CM; Yu R; Chen YJ
Medicine (Baltimore); 2016 Feb; 95(7):e2836. PubMed ID: 26886644
[TBL] [Abstract][Full Text] [Related]
8. Nonhypervascular Pancreatic Neuroendocrine Tumors: Differential Diagnosis from Pancreatic Ductal Adenocarcinomas at MR Imaging-Retrospective Cross-sectional Study.
Jeon SK; Lee JM; Joo I; Lee ES; Park HJ; Jang JY; Ryu JK; Lee KB; Han JK
Radiology; 2017 Jul; 284(1):77-87. PubMed ID: 28092495
[TBL] [Abstract][Full Text] [Related]
9. Reassessment of the current American Joint Committee on Cancer staging system for pancreatic neuroendocrine tumors.
Qadan M; Ma Y; Visser BC; Kunz PL; Fisher GA; Norton JA; Poultsides GA
J Am Coll Surg; 2014 Feb; 218(2):188-95. PubMed ID: 24321190
[TBL] [Abstract][Full Text] [Related]
10. Clinical Characteristics and Prognostic Factors of Early-Onset Pancreatic Neuroendocrine Tumors.
Shi M; Zhou B
Cancer Control; 2021; 28():1073274820986827. PubMed ID: 33491476
[TBL] [Abstract][Full Text] [Related]
11. A prognostic nomogram in patients with distant metastasis of pancreatic neuroendocrine tumors: a population-based study.
Cai JS; Chen HY; Lu YF; Yu RS
Future Oncol; 2020 Jan; 16(2):4369-4379. PubMed ID: 31802701
[No Abstract] [Full Text] [Related]
12. Correlation of Histological Vessel Characteristics and Diffusion-Weighted Imaging Intravoxel Incoherent Motion-Derived Parameters in Pancreatic Ductal Adenocarcinomas and Pancreatic Neuroendocrine Tumors.
Klau M; Mayer P; Bergmann F; Maier-Hein K; Hase J; Hackert T; Kauczor HU; Grenacher L; Stieltjes B
Invest Radiol; 2015 Nov; 50(11):792-7. PubMed ID: 26186280
[TBL] [Abstract][Full Text] [Related]
13. Nonhypervascular pancreatic neuroendocrine tumors: Spectrum of MDCT imaging findings and differentiation from pancreatic ductal adenocarcinoma.
Karmazanovsky G; Belousova E; Schima W; Glotov A; Kalinin D; Kriger A
Eur J Radiol; 2019 Jan; 110():66-73. PubMed ID: 30599875
[TBL] [Abstract][Full Text] [Related]
14. Non-functional pancreatic neuroendocrine tumours: emerging trends in incidence and mortality.
Wu J; Sun C; Li E; Wang J; He X; Yuan R; Yi C; Liao W; Wu L
BMC Cancer; 2019 Apr; 19(1):334. PubMed ID: 30961556
[TBL] [Abstract][Full Text] [Related]
15. Palliative Resection of Primary Tumor in Metastatic Nonfunctioning Pancreatic Neuroendocrine Tumors.
Ye H; Xu HL; Shen Q; Zheng Q; Chen P
J Surg Res; 2019 Nov; 243():578-587. PubMed ID: 31031022
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic neuroendocrine tumours: Grade is superior to T, N, or M status in predicting outcome and selecting patients for chemotherapy:A retrospective cohort study in the SEER database.
Zhai H; Li D; Feng Q; Qian X; Li L; Yao J
Int J Surg; 2019 Jun; 66():103-109. PubMed ID: 30872175
[TBL] [Abstract][Full Text] [Related]
17. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors.
Bilimoria KY; Bentrem DJ; Merkow RP; Tomlinson JS; Stewart AK; Ko CY; Talamonti MS
J Am Coll Surg; 2007 Oct; 205(4):558-63. PubMed ID: 17903729
[TBL] [Abstract][Full Text] [Related]
18. Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis.
Blackford AL; Canto MI; Klein AP; Hruban RH; Goggins M
J Natl Cancer Inst; 2020 Nov; 112(11):1162-1169. PubMed ID: 31958122
[TBL] [Abstract][Full Text] [Related]
19. It's more than just cancer biology: Health disparities in patients with pancreatic neuroendocrine tumors.
Underwood PW; Riner AN; Neal D; Cameron ME; Yakovenko A; Reddy S; Rose JB; Hughes SJ; Trevino JG
J Surg Oncol; 2021 Dec; 124(8):1390-1401. PubMed ID: 34499741
[TBL] [Abstract][Full Text] [Related]
20. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm.
Mirkin KA; Hollenbeak CS; Wong J
J Surg Res; 2017 May; 211():206-214. PubMed ID: 28501118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
